Research graph
References from The <scp>PART</scp> randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
EAU‐EANM‐ESTRO‐ESUR‐ISUP‐SIOG guidelines on prostate Cancer‐2024 update. Part I: screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2024.03.027 · 2024 · External reference
Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023 · External reference
The index lesion and the origin of prostate cancer
10.1056/nejmcibr0905562 · 2009 · External reference
Targeting the cancer lesion, not the whole prostate
10.21037/tau.2019.09.12 · 2020 · External reference
Focal therapy for localized prostate cancer in the era of routine multi‐parametric MRI
10.1038/s41391-020-0206-6 · 2020 · External reference
Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions
10.1016/j.prnil.2025.07.002 · 2026 · External reference
Cancer control outcomes following focal therapy using high‐intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi‐institute 15‐year experience
10.1016/j.eururo.2022.01.005 · 2022 · External reference
Focal therapies for localized prostate cancer
10.1016/j.ucl.2025.09.010 · 2026 · External reference
Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound
10.1111/bju.16122 · 2023 · External reference
Irreversible electroporation for partial gland ablation: clinical application and outcomes
10.1016/j.prnil.2025.08.002 · 2026 · External reference
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy – a comprehensive review
10.1038/s41391-025-00956-x · 2026 · External reference
Whole‐gland or subtotal high‐intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial
10.1016/j.eururo.2024.11.006 · 2025 · External reference
Irreversible electroporation for prostate tissue ablation in patients with intermediate‐risk prostate cancer: results from the PRESERVE trial
10.1016/j.eururo.2025.06.003 · 2026 · External reference
Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
10.1016/s0140-6736(16)32401-1 · 2017 · External reference
MRI‐targeted or standard biopsy for prostate‐cancer diagnosis
10.1056/nejmoa1801993 · 2018 · External reference
NCCN guidelines® insights: prostate cancer, version 5.2026
10.6004/jnccn.2026.0023 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Partial ablation versus radical prostatectomy in intermediate‐risk prostate cancer: the PART feasibility RCT
10.3310/hta22520 · 2018 · External reference
Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
10.1111/bju.14432 · 2018 · External reference
Interval estimation for the difference between independent proportions: comparison of eleven methods
10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · 1998 · External reference
Focal therapy compared to radical prostatectomy for non‐metastatic prostate cancer: a propensity score‐matched study
10.1038/s41391-020-00315-y · 2021 · External reference
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6‐year tumour control
10.1038/s41391-021-00369-6 · 2021 · External reference
Evaluating the trade‐offs men with locasied prostate cancer make between the risks and benefits of treatments: the COMPARE study
10.1097/ju.0000000000000754 · 2020 · External reference
Unresolved reference
External reference
Final, three‐year oncological results of a randomized clinical trial (FARP) comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer
2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Interval estimation for the difference between independent proportions: comparison of eleven methods
10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · ExternalCitation · doi-reference
Cancer control outcomes following focal therapy using high‐intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi‐institute 15‐year experience
10.1016/j.eururo.2022.01.005 · ExternalCitation · doi-reference
EAU‐EANM‐ESTRO‐ESUR‐ISUP‐SIOG guidelines on prostate Cancer‐2024 update. Part I: screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2024.03.027 · ExternalCitation · doi-reference
Whole‐gland or subtotal high‐intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial
10.1016/j.eururo.2024.11.006 · ExternalCitation · doi-reference
Irreversible electroporation for prostate tissue ablation in patients with intermediate‐risk prostate cancer: results from the PRESERVE trial
10.1016/j.eururo.2025.06.003 · ExternalCitation · doi-reference
Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions
10.1016/j.prnil.2025.07.002 · ExternalCitation · doi-reference
Irreversible electroporation for partial gland ablation: clinical application and outcomes
10.1016/j.prnil.2025.08.002 · ExternalCitation · doi-reference
Focal therapies for localized prostate cancer
10.1016/j.ucl.2025.09.010 · ExternalCitation · doi-reference
Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
10.1016/s0140-6736(16)32401-1 · ExternalCitation · doi-reference
Focal therapy compared to radical prostatectomy for non‐metastatic prostate cancer: a propensity score‐matched study
10.1038/s41391-020-00315-y · ExternalCitation · doi-reference
Focal therapy for localized prostate cancer in the era of routine multi‐parametric MRI
10.1038/s41391-020-0206-6 · ExternalCitation · doi-reference
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6‐year tumour control
10.1038/s41391-021-00369-6 · ExternalCitation · doi-reference
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy – a comprehensive review
10.1038/s41391-025-00956-x · ExternalCitation · doi-reference
The index lesion and the origin of prostate cancer
10.1056/nejmcibr0905562 · ExternalCitation · doi-reference
MRI‐targeted or standard biopsy for prostate‐cancer diagnosis
10.1056/nejmoa1801993 · ExternalCitation · doi-reference
Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · ExternalCitation · doi-reference
Evaluating the trade‐offs men with locasied prostate cancer make between the risks and benefits of treatments: the COMPARE study
10.1097/ju.0000000000000754 · ExternalCitation · doi-reference
Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
10.1111/bju.14432 · ExternalCitation · doi-reference
Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound
10.1111/bju.16122 · ExternalCitation · doi-reference
Targeting the cancer lesion, not the whole prostate
10.21037/tau.2019.09.12 · ExternalCitation · doi-reference
Partial ablation versus radical prostatectomy in intermediate‐risk prostate cancer: the PART feasibility RCT
10.3310/hta22520 · ExternalCitation · doi-reference
NCCN guidelines® insights: prostate cancer, version 5.2026
10.6004/jnccn.2026.0023 · ExternalCitation · doi-reference
